ArticleCurrent oncology (Toronto, Ont.)2021
A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer.
Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Dermatomyositis as a paraneoplastic sign of breast cancer: a case report and literature review.International journal of surgery case reports · 2026Article
- Paraneoplastic dermatomyositis with atypical features associated with a solid pseudopapillary pancreatic neoplasm.Clinical rheumatology · 2026Review
- Case Report: breast cancer presenting as dermatomyositis.Frontiers in oncology · 2026Article
- Case report: Malignant erythema in an ovarian cancer case: an uncommon paraneoplastic syndrome.Frontiers in oncology · 2026Article
- Rare diagnosis of locally advanced triple‑negative breast cancer with paraneoplastic dermatomyositis: A case report and literature review.Oncology letters · 2025Article
- Association Between Anti-TIF1-γ Antibody and Triple-Negative Breast Carcinoma in Dermatomyositis Patients: A Case Report.Clinical case reports · 2025Article
- Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery.International cancer conference journal · 2024Article
- Triple-Negative Breast Cancer with Dermatomyositis: A Case Report and Literature Review.Cancer management and research · 2022Article
- Preoperative Systemic Chemotherapy Including Immune Checkpoint Inhibitors for Patients with Tumor-Associated Dermatomyositis.Case reports in oncologyArticle
- Chemo- and Immunotherapy in a Patient with Anti-TIF1γ-Positive Paraneoplastic Dermatomyositis in Adenocarcinoma of Unknown Primary Origin: A Challenging Path from Diagnosis to Treatment - A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. CASE PRESENTATION: A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness, heliotropic rash and left breast rash. Muscle biopsy findings were consistent with dermatomyositis (DM). A full panel of myositis associated (MAA) and specific antibodies (MSA) revealed the presence of anti-nuclear antibodies (1:160, speckled), Anti-Ro52 and anti TIF1-γ antibodies. A whole body Computed Tomography Scan showed three left mammary nodules and homolateral axillary lymphadenopathy. The breast biopsy confirmed the diagnosis of ductal carcinoma. Patient was initiated to neoadjuvant chemotherapy followed by surgery for cancer, and corticosteroid and intravenous immunoglobulins for DM with a complete resolution of muscle weakness and pathological complete response of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.